Evolution of the European guidelines for the clinical development of factor VIII products: Little progress towards improved patient management

Haemophilia

Volumn 19, Issue 3, 2013, Pages 344-348

  Mannucci, P M ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Clinical trial guidelines; Factor VIII; Factor VIII inhibitors; Haemophilia A; Safety

Indexed keywords

BLOOD CLOTTING FACTOR 8 DERIVATIVE; BLOOD CLOTTING FACTOR 8 INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 8;

BLEEDING; CLINICAL DEVELOPMENT PLAN; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; EUROPE; FOLLOW UP; HEMOPHILIA A; HUMAN; PATIENT CARE; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

BLOOD COAGULATION FACTOR INHIBITORS; FACTOR VIII; GUIDELINES AS TOPIC; HALF-LIFE; HEMOPHILIA A; HUMANS; VIRUS INACTIVATION;

EID: 84876801691     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12041     Document Type: Review

References (15)

1. Plug I, Van DerBom JG, Peters M et al. Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study. J Thromb Haemost 2006; 4: 510-6.
2. Tagliaferri A, Rivolta GF, Iorio A et al. Mortality and causes of death in Italian persons with haemophilia, 1990-2007. Haemophilia 2010; 16: 437-46.
3. McMillan CW, Shapiro SS, Whitehurst D, Hoyer LW, Rao AV, Lazerson J. The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors. Blood 1988; 71: 344-8.
4. Kempton CL, Soucie JM, Abshire TC. Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates. J Thromb Haemost 2006; 4: 2576-81.
5. Hay CR, Palmer B, Chalmers E et al. Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood 2011; 117: 6367-70.
6. Peerlinck K, Arnout J, Gilles JG, Saint-Remy JM, Vermylen J. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. Thromb Haemost 1993; 69: 115-8.
7. Rosendaal FR, Nieuwenhuis HK, Van DenBerg HM et al. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study Group. Blood 1993; 81: 2180-6.
8. Blood safety monitoring among persons with bleeding disorders-United States. May 1998-June 2002. MMWR Morb Mortal Wkly Rep 2003; 51: 1152-4.
9. Schwaab R, Brackmann HH, Meyer C et al. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost 1995; 74: 1402-6.
10. Astermark J, Berntorp E. Malmo International Brother Study (MIBS): an international survey of brother pairs with haemophilia. Vox Sang 1999; 77(Suppl 1): 80-2.
11. Aledort LM, Dimichele DM. Inhibitors occur more frequently in African-American and Latino haemophiliacs. Haemophilia 1998; 4: 68.
12. Oldenburg J, Picard JK, Schwaab R, Brackmann HH, Tuddenham EG, Simpson E. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII. Thromb Haemost 1997; 77: 238-42.
13. Sharathkumar A, Lillicrap D, Blanchette VS et al. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. J Thromb Haemost 2003; 1: 1228-36.
14. Mannucci PM, Mancuso ME, Santagostino E. How we choose factor VIII to treat hemophilia. Blood 2012; 119: 4108-14.
15. Aledort LM. Harmonization of clinical trial guidelines for assessing the risk of inhibitor development in hemophilia A treatment. J Thromb Haemost 2011; 9: 423-7.